Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fo

WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central

Related Keywords

Helen Shik , Remy Luthringer , Frederick Ahlholm , Minerva Neurosciences , Janssen Pharmaceutica , Development Rd Expenses , Shik Communications , Drug Administration , Minerva Neurosciences Inc , Johnson , Nasdaq , New Drug Application , Label Extension , Royalty Pharma , Executive Chairman , Chief Executive Officer , Open Label Extension , Negative Syndrome Scale , Marder Negative Symptom Factor Score , Social Performance , In Process Research , Private Securities Litigation Reform Act , Term Liabilities , Months Ended December , Aminerva , Neurosciences , Reports , Fourth , Quarter , 021 , Financial , Results , Business , Updates ,